Literature DB >> 31342463

The spontaneous clearance of hepatitis E virus (HEV) and emergence of HEV antibodies in a transfusion-transmitted chronic hepatitis E case after completion of chemotherapy for acute myeloid leukemia.

Hiroshi Okano1, Tatsunori Nakano2, Ryugo Ito3, Ami Tanaka4, Yuji Hoshi4, Keiji Matsubayashi4, Hiroki Asakawa5, Kenji Nose5, Satomi Tsuruga5, Tomomasa Tochio5, Hiroaki Kumazawa5, Yoshiaki Isono5, Hiroki Tanaka5, Shimpei Matsusaki5, Tomohiro Sase5, Tomonori Saito5, Katsumi Mukai5, Akira Nishimura5, Keiki Kawakami3, Shigeo Nagashima6, Masaharu Takahashi6, Hiroaki Okamoto6.   

Abstract

A 64-year-old woman was infected with hepatitis E virus (HEV) during chemotherapy for leukemia. By retrospective analyses of stored serum from the blood products and the patient, the source of the infection was determined to be platelet concentration (PC) transfused during chemotherapy. The partial nucleotide sequence of the HEV strain isolated from the donated PC and that from the patient's sera was identical and was subgenotype 3b. Clinical indicators such as alanine aminotransferase, HEV RNA titer, and anti-HEV antibodies in the serum were investigated from the beginning of the infection until 1 year after the termination of HEV infection. HEV RNA had propagated over 6 months and then cleared spontaneously after the completion of chemotherapy. Anti-HEV antibodies appeared in the serum just before the clearance of HEV RNA. Interestingly, HEV RNA was detected in the patient's urine, spinal fluid, and saliva. The HEV RNA titers in those samples were much lower than in the serum and feces. No renal, neurological, or salivary gland disorders appeared during the follow-up. We observed virological and biochemical progress and cure of transfusion-transmitted chronic hepatitis E in the patient despite an immunosuppressive status during and after chemotherapy against hematological malignancy.

Entities:  

Keywords:  Chemotherapy; Hematological malignancy; Hepatitis E; Immunosuppression; Transfusion

Mesh:

Substances:

Year:  2019        PMID: 31342463     DOI: 10.1007/s12328-019-01024-3

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  24 in total

1.  Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression.

Authors:  Masahiro Satake; Keiji Matsubayashi; Yuji Hoshi; Rikizo Taira; Yasumi Furui; Norihiro Kokudo; Nobuhisa Akamatsu; Tomoharu Yoshizumi; Nobuhiro Ohkohchi; Hiroaki Okamoto; Masato Miyoshi; Akinori Tamura; Kyoko Fuse; Kenji Tadokoro
Journal:  Transfusion       Date:  2017-01-31       Impact factor: 3.157

2.  Transfusion-transmitted hepatitis E in a patient with myelodysplastic syndromes.

Authors:  Yukihiko Kimura; Akihiko Gotoh; Seiichiro Katagiri; Yuji Hoshi; Shigeharu Uchida; Atsushi Yamasaki; Yoko Takahashi; Katsuyuki Fukutake; Toru Kiguchi; Kazuma Ohyashiki
Journal:  Blood Transfus       Date:  2013-10-02       Impact factor: 3.443

3.  Hepatitis E.

Authors:  Jay H Hoofnagle; Kenrad E Nelson; Robert H Purcell
Journal:  N Engl J Med       Date:  2012-09-27       Impact factor: 91.245

4.  Hepatitis E virus excretion can be prolonged in patients with hematological malignancies.

Authors:  Suzanne Tavitian; Jean-Marie Péron; Anne Huynh; Jean-Michel Mansuy; Loic Ysebaert; Françoise Huguet; Jean-Pierre Vinel; Michel Attal; Jacques Izopet; Christian Récher
Journal:  J Clin Virol       Date:  2010-08-01       Impact factor: 3.168

5.  Late onset post-transfusion hepatitis E developing during chemotherapy for acute promyelocytic leukemia.

Authors:  Kyoko Fuse; Yuichi Matsuyama; Masato Moriyama; Shukuko Miyakoshi; Yasuhiko Shibasaki; Jun Takizawa; Tatsuo Furukawa; Ichiro Fuse; Hiro Matsumura; Shigeharu Uchida; Yoshifumi Takahashi; Kenya Kamimura; Hiroyuki Abe; Takeshi Suda; Yutaka Aoyagi; Hirohito Sone; Masayoshi Masuko
Journal:  Intern Med       Date:  2015-01-15       Impact factor: 1.271

Review 6.  Hepatitis E virus - key points for the clinical haematologist.

Authors:  Joanne O'Gorman; Áine Burke; Niamh O'Flaherty
Journal:  Br J Haematol       Date:  2018-02-21       Impact factor: 6.998

7.  Prolonged fecal shedding of hepatitis E virus (HEV) during sporadic acute hepatitis E: evaluation of infectivity of HEV in fecal specimens in a cell culture system.

Authors:  Masaharu Takahashi; Toshinori Tanaka; Masahiro Azuma; Eiji Kusano; Tatsuya Aikawa; Takao Shibayama; Yasuyuki Yazaki; Hitoshi Mizuo; Jun Inoue; Hiroaki Okamoto
Journal:  J Clin Microbiol       Date:  2007-08-29       Impact factor: 5.948

8.  Production of monoclonal antibodies against hepatitis E virus capsid protein and evaluation of their neutralizing activity in a cell culture system.

Authors:  Masaharu Takahashi; Yu Hoshino; Toshinori Tanaka; Hideyuki Takahashi; Tsutomu Nishizawa; Hiroaki Okamoto
Journal:  Arch Virol       Date:  2008-02-12       Impact factor: 2.574

Review 9.  Culture systems for hepatitis E virus.

Authors:  Hiroaki Okamoto
Journal:  J Gastroenterol       Date:  2012-10-27       Impact factor: 7.527

10.  Hepatitis E during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis: Case Report and Literature Review.

Authors:  Hidekazu Ikeuchi; Kana Koinuma; Masao Nakasatomi; Toru Sakairi; Yoriaki Kaneko; Akito Maeshima; Yuichi Yamazaki; Hiroaki Okamoto; Toshihide Mimura; Satoshi Mochida; Yoshihisa Nojima; Keiju Hiromura
Journal:  Case Rep Rheumatol       Date:  2018-07-26
View more
  1 in total

Review 1.  Transfusion-transmitted hepatitis E: What we know so far?

Authors:  Carmen Ka Man Cheung; Sunny Hei Wong; Alvin Wing Hin Law; Man Fai Law
Journal:  World J Gastroenterol       Date:  2022-01-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.